Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19320635 | 0.92 | OPRL1 (0.54) | OPRL1POLBKMT2ACCR3CYP3A4 | |
| SCHEMBL9179575 | 0.89 | OPRL1 (0.48) | OPRL1POLBKMT2AKDM4ECCR3 | |
| SCHEMBL9175281 | 0.85 | OPRL1 (0.49) | OPRL1POLBKMT2AKDM4ECCR3 | |
| SCHEMBL19322400 | 0.83 | OPRL1 (0.53) | OPRL1POLBKMT2AKDM4ECCR3 | |
| Hydrochloric Acid SCHEMBL9179035 | 0.82 | POLB (0.54) | OPRL1POLBKMT2AKDM4ECCR3 | |
| SCHEMBL3222218 | 0.82 | OPRL1 (0.51) | OPRL1POLBKMT2AKDM4ECCR3 | |
| Hydrochloric Acid SCHEMBL9718148 | 0.82 | POLB (0.54) | OPRL1POLBKMT2AKDM4ECCR3 | |
| SCHEMBL17606266 | 0.80 | OPRL1 (0.49) | OPRL1POLBKMT2AKDM4ECCR3 | |
| SCHEMBL17609039 | 0.79 | NPFFR1 (0.48) | OPRL1POLBCYP3A4CYP2D6TSHR | |
| SCHEMBL9178518 | 0.78 | OPRL1 (0.48) | OPRL1POLBKMT2AKDM4ECCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515965-B1 | PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2010-10-06 | — | — | EP | disclosed |
| EP-1515965-B1 | PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2010-10-06 | — | — | EP | disclosed |
| US-7091198-B1 | 2,5-disubstituted pyrimidine derivatives | BAYER HEALTHCARE AG (DE) | 2006-08-15 | — | — | US | disclosed |
| US-20060167016-A1 | 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1525202-B1 | NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1525202-A1 | NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1515965-A1 | PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS | Bayer Aktiengesellschaft (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004009589-A1 | NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003106450-A1 | PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167016-A1 | 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES | PDE7A, P2RY2, CGAS | OPRL1 901/4885POLB 3442/4885KMT2A 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.